UBS Group’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-3,869,063
| Closed | -$23.3M | – | 8846 |
|
|
2019
Q4 | $23.3M | Sell |
3,869,063
-2,064,770
| -35% | -$12M | 0.01% | 1269 |
|
|
2019
Q3 | $21.4M | Buy |
5,933,833
+358,305
| +6% | +$1.38M | 0.01% | 1188 |
|
|
2019
Q2 | $14.9M | Buy |
5,575,528
+1,824,534
| +49% | +$5.39M | 0.01% | 1427 |
|
|
2019
Q1 | $11.1M | Buy |
3,750,994
+2,372,427
| +172% | +$5.83M | ﹤0.01% | 1599 |
|
|
2018
Q4 | $2.19M | Buy |
1,378,567
+1,312,467
| +1,986% | +$3.71M | ﹤0.01% | 2945 |
|
|
2018
Q3 | $243K | Buy |
66,100
+33,640
| +104% | +$100K | ﹤0.01% | 4920 |
|
|
2018
Q2 | $92K | Sell |
32,460
-272,677
| -89% | -$929K | ﹤0.01% | 5505 |
|
|
2018
Q1 | $1.13M | Buy |
305,137
+207,824
| +214% | +$680K | ﹤0.01% | 3609 |
|
|
2017
Q4 | $280K | Sell |
97,313
-31,801
| -25% | -$116K | ﹤0.01% | 4684 |
|
|
2017
Q3 | $580K | Buy |
129,114
+44,006
| +52% | +$195K | ﹤0.01% | 4108 |
|
|
2017
Q2 | $391K | Sell |
85,108
-14,309
| -14% | -$57.5K | ﹤0.01% | 4292 |
|
|
2017
Q1 | $419K | Sell |
99,417
-95,600
| -49% | -$397K | ﹤0.01% | 4168 |
|
|
2016
Q4 | $806K | Buy |
195,017
+42,347
| +28% | +$225K | ﹤0.01% | 3736 |
|
|
2016
Q3 | $1.24M | Sell |
152,670
-40,701
| -21% | -$346K | ﹤0.01% | 3266 |
|
|
2016
Q2 | $1.51M | Buy |
193,371
+10,109
| +6% | +$86.7K | ﹤0.01% | 3011 |
|
|
2016
Q1 | $1.42M | Sell |
183,262
-248,075
| -58% | -$1.82M | ﹤0.01% | 2977 |
|
|
2015
Q4 | $4.66M | Buy |
431,337
+194,410
| +82% | +$1.77M | ﹤0.01% | 2026 |
|
|
2015
Q3 | $1.64M | Buy |
236,927
+381
| +0.2% | +$3.1K | ﹤0.01% | 2916 |
|
|
2015
Q2 | $2.1M | Buy |
236,546
+11,417
| +5% | +$108K | ﹤0.01% | 2932 |
|
|
2015
Q1 | $2.22M | Buy |
225,129
+82,052
| +57% | +$1.02M | ﹤0.01% | 2834 |
|
|
2014
Q4 | $1.75M | Buy |
+143,077
| New | +$1.75M | ﹤0.01% | 3027 |
|
UBS Group's ACHN Position: Q1 2020 in Review
UBS Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 3,869,063 shares — an estimated $23.3M sold.
UBS Group first reported a position in ACHN in Q4 2014 and held it in 21 quarters. The position peaked at $23.3M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- UBS Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 3,869,063 Achillion Pharmaceuticals shares in Q1 2020, an estimated $23.3M.
- UBS Group first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 21 quarters.
- UBS Group's Achillion Pharmaceuticals position peaked at $23.3M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.